Compounded semaglutide associated with at least 10 deaths, Novo Nordisk CEO warns
By Meg Tirrell, CNN (CNN) — Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have been associated with at least 100 hospitalizations and 10 deaths, the chief executive of Ozempic maker Novo Nordisk warned Wednesday. “Honestly, I’m quite alarmed by what we see in the US now,”
Continue Reading